| |
|
Department of Urology Home
Contact Us
About Us
Patient Care
Services
Appointments
Faculty and Staff
Patent and Visitor Information
Hospital Directions
Educational Materials
Education
Residency Program
Fellowship Program
Current Residents
UI Graduate Medical Education
Urology Electronic Resource Center
Clinical Trials
Research
J. Hayden Fry Center for Prostate Cancer Research
Bladder Cancer Research
David M. Lubaroff Laboratory
Providers
Referring Physician Resources
Flocks Urological Society
News and Events
|
|
|
Yi Luo, MD, PhD
Assistant Professor
Urologic Oncology Research
Education
- 1978 Nanjing Medical University, China, MD
- 1982 Nanjing Medical University, China, MS
- 1994 University of New Brunswick, Canada, PhD
Postgraduate Training
- 1987-89 Research Fellow, Department of Molecular Immunology. Roswell Park Cancer Institute, Buffalo
- 1994-96 Postdoctoral Fellow, Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston
Academic Positions
- 1983-86 Lecturer, Biochemistry, Nanjing Medical University, China
- 1996-2000 Instructor, Surgery, Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston
- 2000-02 Associate Research Scientist, University of Iowa Department of Urology
- 2002-04 Faculty Associate, University of Iowa Department of Urology
- 2004 Assistant Professor, University of Iowa Department of Urology
Affiliations
- 1998 American Association for Cancer Research
- 2000 American Association for The Advancement of Science
- 2003 Society for Basic Urologic Research
- 2004 University of Iowa Holden Comprehensive Cancer Center
Honors
- 1989-93 Graduate Fellowship Award, University of New Brunswick, Canada
- 1996-98 American Foundation for Urologic Disease PhD Research Scholar
- 2001-03 Pharmacia 2001 Ellence Research Fund
- 2001-02 American Cancer Society Seed Grant
- 2003 American Urological Association Traveling Fellowship Award
Research Interests
- Bladder cancer immunotherapy
- Bladder immunogenic/autoimmune disorders
- Peptide-based targeting therapy
- Recombinant BCG development
- Urothelium-specific transgenic modeling
|
|
|